[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Greenson JK: Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol; 2003 Apr;16(4):366-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Along with this understanding comes an exciting new drug therapy (Gleevec) that for the first time offers real hope to patients with malignant stromal tumors.
  • Overall, approximately 60-70% of stromal tumors are from the stomach, 20-30% are from the small intestine, and <10% come from the esophagus, colon, rectum, omentum, and mesentery.
  • Between 10 and 30% of GISTs are malignant.
  • Although the most important tool needed to diagnose a GIST is still a hematoxylin and eosin-stained section, a confirmatory CD117 stain is recommended (and may be required for drug therapy).
  • True smooth muscle tumors, inflammatory fibroid polyps, fibromatoses, schwannomas, inflammatory myofibroblastic tumors, and solitary fibrous tumors all enter into the differential diagnosis of GISTs.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gastrointestinal Neoplasms / pathology. Mesoderm / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Diagnosis, Differential. Imatinib Mesylate. Immunohistochemistry. Molecular Biology. Piperazines / therapeutic use. Prognosis. Pyrimidines / therapeutic use

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12692202.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 55
  •  go-up   go-down


2. Castillo-Sang M, Mancho S, Tsang AW, Gociman B, Almaroof B, Ahmed MY: A malignant omental extra-gastrointestinal stromal tumor on a young man: a case report and review of the literature. World J Surg Oncol; 2008;6:50
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A malignant omental extra-gastrointestinal stromal tumor on a young man: a case report and review of the literature.
  • In fewer than 5% of cases, they originate primarily from the mesentery, omentum, or peritoneum.
  • An abdominal pelvic computerized tomography imaging demonstrated an intra-abdominal mass of 22 cm, without invasion of adjacent viscera or liver lesions.
  • This mass was resected en bloc with its fused omentum and an adherent portion of sigmoid colon.
  • Pathology results demonstrated a malignant gastrointestinal stromal tumor with positive CD117 (c-kit) staining, and negative margins of resection, and no continuity of tumor with the sigmoid colon.
  • Due to the malignant and aggressive nature of this patient's tumor, he was started on STI-571 as adjuvant chemotherapy.
  • Young patients who present with an extra-gastrointestinal stromal tumor (EGIST), who have complete resection with negative margins, have a good prognosis.
  • There is little data to support the role of STI-571 in adjuvant or neoadjuvant therapy after curative resection.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Omentum. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Benzamides. Humans. Imatinib Mesylate. Male. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / analysis. Pyrimidines / therapeutic use

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):82-7 [9888707.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1109-18 [10478672.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Jun;19(3):547-64, vii [15939196.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1373-81 [16160481.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Am J Surg. 2007 Aug;194(2):148-52 [17618793.001]
  • [Cites] World J Surg Oncol. 2007;5:66 [17565683.001]
  • [Cites] Mod Pathol. 2000 May;13(5):577-85 [10824931.001]
  • [Cites] Pathol Int. 2001 Jul;51(7):524-31 [11472565.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8118-21 [11719439.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Hum Pathol. 2002 May;33(5):466-77 [12094371.001]
  • [Cites] Hum Pathol. 2002 May;33(5):478-83 [12094372.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):479-88 [15087667.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):39-50 [15221987.001]
  • (PMID = 18479530.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2409333
  •  go-up   go-down


3. Ridwelski K, Meyer F, Hribaschek A, Kasper U, Lippert H: Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis. J Surg Oncol; 2002 Jan;79(1):10-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis.
  • BACKGROUND AND OBJECTIVES: Malignant tumors of various abdominal organs are blamed to be the cause of death in approximately 40% of cases per year in Western Europe.
  • At the time of death, about half of them show peritoneal carcinomatosis which is considered an unfavorable prognostic factor.
  • In case of peritoneal carcinomatosis, there is no curative treatment available for any of the tumors in the abdominal cavity.
  • Extension of this carcinomatosis was quantified by (i) counting tumor nodes per square centimeter (mean of several counts) and (ii) determining tumor weight (weight of the greater omentum plus the resected mesentery).
  • Rats were subdivided into three groups (n = 6 per group): group 1 (controls); group 2, simultaneously with tumor cell transfer 24 mg/kg of gemcitabine were administered into the abdominal cavity; group 3, postoperative intraperitoneal irrigation with 24 mg/kg of gemcitabine was achieved via a previously implanted port-a-cath on days(d) 15, 21, and 27.
  • RESULTS: On the 30th postoperative day, all six animals of the control group showed extensive tumor growth at the peritoneum and greater omentum, indicating carcinomatosis.
  • In contrast, none of the rats of group 2 revealed any traces of intraperitoneal tumor growth.
  • While all rats of group 3 demonstrated intraperitoneal tumor growth, but early postoperative treatment with gemcitabine, however, resulted in a significant reduction of the number of tumor nodes and tumor weight in comparison with group 1 (controls).
  • CONCLUSIONS: Immediate, i.e., simultaneous intraoperative application of a cytostatic agent such as gemcitabine into the abdominal cavity may completely prevent the generation of peritoneal carcinomatosis from occuring tumor cells, whereas early postoperative locoregional chemotherapy into the abdominal cavity can only reduce the severity of the peritoneal carcinomatosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Neoplasm Seeding. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Animals. Disease Models, Animal. Drug Administration Schedule. Infusions, Parenteral. Intraoperative Care. Male. Postoperative Care. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11754372.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


Advertisement
4. Baker JM, Viero S, Kim PC, Grant RM: Stage III cystic partially differentiated nephroblastoma recurring after nephrectomy and chemotherapy. Pediatr Blood Cancer; 2008 Jan;50(1):129-31
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage III cystic partially differentiated nephroblastoma recurring after nephrectomy and chemotherapy.
  • Cystic partially differentiated nephroblastoma (CPDN) has low malignant potential.
  • We report a 1-year-old with stage III CPDN of the right kidney that recurred following radical nephrectomy and chemotherapy.
  • There was evidence of tumor spillage pre-operatively and intra-operatively.
  • During chemotherapy the disease recurred in the omentum and the peritoneum.
  • Pathology of the recurrent resected cysts revealed a more differentiated biphasic tumor without blastemal elements.
  • Chemotherapy failed to prevent recurrence but only mature elements were present following this treatment.
  • The intensity of therapy required to treat CPDN remains undefined.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / therapy. Nephrectomy. Wilms Tumor / secondary. Wilms Tumor / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Infant. Peritoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 16786584.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Billmire D, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, Davis M, Giller R, Lauer S, Olson T, Children's Oncology Group (COG): Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg; 2004 Mar;39(3):424-9; discussion 424-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study.
  • PURPOSE: The aim of this study was to perform an evaluation of outcome and the role of surgical staging components in malignant germ cell tumors (GCT) of the ovary in children and adolescents.
  • METHODS: From 1990 to 1996, 2 intergroup trials for malignant GCT were undertaken by Pediatric Oncology Group (POG) and Children's Cancer Study Group (CCG).
  • Stage I-II patients were treated with surgical resection and 4 cycles of standard dose cisplatin (100 mg/m2/cycle), etoposide, and bleomycin (PEB) chemotherapy.
  • Stage III-IV patients were treated with surgical resection and randomly assigned to chemotherapy with PEB or high-dose cisplatin (200 mg/m2/cycle) with etoposide and bleomycin (HDPEB).
  • Patients unresectable at diagnosis had second-look operation after 4 cycles of chemotherapy if residual tumor was seen on imaging studies.
  • More aggressive procedure than recommended by guidelines included total hysterectomy and bilateral salpingo-oophorectomy in 6 patients and retroperitoneal node dissection in 10 patients.
  • Correlation of gross operative findings with pathology results was carried out for ascites, lymph nodes, implants, omentum, and contralateral ovary.
  • CONCLUSIONS: Pediatric ovarian malignant GCT (stages I-IV) have excellent survival with conservative surgical resection and platinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Germinoma / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Female. Humans. Infant. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017564.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


6. Liu YC, Kuo YL, Yu CP, Wu HS, Yu JC, Chen CJ, Chan DC, Yu CY, Hsieh CB, Chen TW: Primary malignant mesothelioma of the greater omentum: report of a case. Surg Today; 2004;34(9):780-3
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant mesothelioma of the greater omentum: report of a case.
  • We report a rare case of primary malignant mesothelioma of the greater omentum.
  • Abdominal sonography and computed tomography showed a 12 x 9 x 9-cm(3) mass occupying the lower abdomen.
  • Laparotomy revealed a tumor in the greater omentum, invading the posterior wall of the uterus, without diffuse mesenteric thickening or multiple small nodules in the peritoneum.
  • Microscopically, the tumor cells were arranged in a tubulopapillary pattern lined by a single layer of uniform, cuboidal cells.
  • Immunohistochemically, the tumor cells showed strong positivity for calretinin.
  • The final pathologic diagnosis was malignant mesothelioma.
  • The patient did not receive chemotherapy or radiotherapy, and has remained in good health without any evidence of recurrence for almost 3 years since her operation.
  • [MeSH-major] Mesothelioma / pathology. Mesothelioma / surgery. Omentum / pathology. Omentum / surgery. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Laparotomy. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15338355.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Chow SN, Lin MC, Shen J, Wang S, Jong YJ, Chien CH: Analysis of chromosome abnormalities by comparative genomic hybridization in malignant peripheral primitive neuroectodermal tumor of the ovary. Gynecol Oncol; 2004 Mar;92(3):752-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of chromosome abnormalities by comparative genomic hybridization in malignant peripheral primitive neuroectodermal tumor of the ovary.
  • OBJECTIVE: Malignant primitive neuroectodermal tumor (PNET) originating from the ovary rather than from the central nervous system is extremely rare.
  • The aim of this study is to demonstrate the chromosomal abnormalities in a case of peripheral primitive neuroectodermal tumor (PPNET) arising from the ovary of a girl.
  • METHODS: The 13-year-old girl underwent exploratory laparotomy because of a huge pelvic tumor in lower abdomen and pelvis.
  • She underwent removal of ovaries, tubes, omentum, peritoneal nodules, and portion of urinary bladder.
  • Tumor specimens were sent for pathology, short-term tissue culture, and for storage in deep freezer for laboratory studies.
  • Immunohistochemical stainings of the tumor with antibodies against O-13 (MIC/CD99), NSE, GFAP, S-100, cytokeratin AE1/AE3, desmin, NF, and AFP were performed.
  • Short-term cell culture of fresh tumor was done for analysis of chromosomal aberrations by the technique of comparative genomic hybridization (CGH).
  • The patient expired 17 months later despite of chemotherapy, repeated surgery, and radiation therapy.
  • RESULT: The histopathology of the specimens revealed malignant neuroectodermal tumor, involving ovaries, tubes, bladder, omentum, and peritoneum.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14984937.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DIRAS3 protein, human; 0 / Retinoblastoma Protein; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


8. Haibin Z, Yue J, Yaxian X: Primary yolk sac tumor of the omentum: a case report and literature review. Eur J Gynaecol Oncol; 2010;31(6):682-4
Genetic Alliance. consumer health - Yolk sac tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary yolk sac tumor of the omentum: a case report and literature review.
  • BACKGROUND: Yolk sac tumor (YST) is the second most common malignant ovarian germ cell tumor, while a YST arising in the omentum is an exceedingly rare malignancy.
  • The alpha-fetoprotein (AFP) serum level was elevated to 27,612 ng/ml, and CT scanning reported an obviously thickened omentum.
  • The patient was treated with total abdominal hysterectomy with bilateral salpingo-oophorectomy and infracolic omentectomy followed by four cycles of bleomycin, etoposide, and cisplatin combination chemotherapy.
  • She has remained free of the disease for seven months after completion of therapy.
  • The subject of YST arising in the omentum is reviewed.
  • The case of omental YST must be seriously considered once the tumor shows omentum thickening with elevated AFP serum levels.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / therapy. Omentum / surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Female. Humans. Hysterectomy. Ovariectomy. Peritoneum / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319517.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


9. Anfinan NM, Sait KH, Al-Maghrabi JA: Primitive neuroectodermal tumor of the ovary. Saudi Med J; 2008 Mar;29(3):444-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor of the ovary.
  • Ovarian tumor markers were all within normal range.
  • Frozen section from the omentum showed metastatic malignant neoplasm.
  • Total abdominal hysterectomy was carried out with bilateral salpingooophorectomy and omentectomy with residual tumor of less then one centimeter.
  • Final pathology assessment showed primitive neuroectodermal tumor arising from the right ovary.
  • She received post- operative chemotherapy.
  • Four months later she had recurrence and was given second line chemotherapy, but she did not respond and died 15 months after the diagnosis due to obstructive uropathy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18327377.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


10. Ami K, Nagahama T, Andou M, Nawa K, Ganno H, Ohbu M, Kimu K, Ito T, Yamauchi A, Ichikawa S, Kobo T, Takaba E: [A case of ascities decrease in malignant peritoneal mesothelioma by weekly intra-peritoneal administration of cisplatin and paclitaxel]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1709-11
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of ascities decrease in malignant peritoneal mesothelioma by weekly intra-peritoneal administration of cisplatin and paclitaxel].
  • We report a case of malignant peritoneal mesothelioma (MPM) in a 63-year-old man.
  • Computed tomography and magnetic resonance image showed a lot of ascites and omentum cake.
  • Then we performed biopsy of the tumor into the omentum with abdominal sonography.
  • The histological diagnosis was MPM because the tumor cells showed positive for calretinin.
  • He received a combination chemotherapy of weekly intra-peritoneal administration of cisplatin (70 mg/ day) and paclitaxel (100 mg/day).
  • The ascites was decreased and per os (PO) was possible, but omentum cake was not changed.
  • We suggest that the chemotherapy of intra-peritoneal administration was a better procedure than others to control ascites with malignant tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ascites / drug therapy. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315916.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Pusiol T, Zorzi MG, Morichetti D, Piscioli I, Scialpi M: Peritoneal Malignant Psammomatous Mesothelioma. World J Oncol; 2010 Aug;1(4):179-181

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal Malignant Psammomatous Mesothelioma.
  • We report one case of peritoneal malignant mesothelioma (PMM) with massive deposition of PBs.
  • Contrast enhanced computed tomography showed fluid diffuse in peritoneal recesses, thick septa with micronodules in the greater omentum and adjacent enhancement of the thickened peritoneum.
  • The peritoneal biopsy revealed a superficial papillary growth of malignant epithelial-like cells with diffuse involvement of submesothelial tissues.
  • The patient was treated with chemotherapy (gemcitabine, vinorelbine, cisplatin).
  • PBs may represent an active biologic process ultimately leading to degeneration/death of tumor cells and retardation of growth of the neoplasm.
  • It may also serve as a barrier against the spread of tumor.
  • Psammomatous malignant mesothelioma may simulate serous psammocarcinoma of the peritoneum.
  • The behavior of serous psammocarcinoma is more closely similar to borderline serous tumor than to serous carcinoma.
  • Further studies are necessary to establish if massive deposition of PBs may define a new variant of psammomatous malignant mesothelioma with a favorable impact to the prognosis of usual psammomatous malignant mesothelioma, as well as in serous psammocarcinoma of the peritoneum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):285-94 [10680897.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):816-23 [10843283.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Histopathology. 2006 Feb;48(3):223-32 [16430468.001]
  • [Cites] Arch Gynecol Obstet. 2009 Jun;279(6):931-6 [18982336.001]
  • [Cites] Acta Med Port. 2002 Sep-Oct;15(5):383-6 [12645223.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Diagn Cytopathol. 2009 Jul;37(7):534-41 [19373908.001]
  • (PMID = 29147203.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Malignant mesothelioma / Psammoma bodies / Psammomatous malignant mesothelioma
  •  go-up   go-down


12. Beck A, Jonas J, Frenzel H, Bähr R: [Gastrointestinal autonomic nerve tumor]. Zentralbl Chir; 2001 Sep;126(9):702-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal autonomic nerve tumor].
  • Gastrointestinal autonomic nerve tumors (GAN-tumor) are rare malignant neurogenic stromal tumors of the intestinal tract.
  • We report on a 53-year-old patient with a clinical apparent and radiological 5 cm measuring tumor of the jejunum, which was resected and immunohistochemically verified as GAN-tumor.
  • Within the follow-up of 29 months metastases appeared within the omentum majus with a diffuse peritoneal spreading.
  • Several trials of adjuvant chemotherapy (adriamycine/ifosamide, taxotere, gemcitabine/xyloda) were ineffective.
  • Since the first description of the GAN-tumor in 1984 87 patients were reported in the literature.
  • A tumor seize of more than 10 cm is associated with recurrences in 64% of the cases within 2 years.
  • Since there is no option for medical treatment, surgical resection is the treatment of choice and has to be considered also in the case of recurrence.
  • [MeSH-major] Autonomic Nervous System Diseases / surgery. Ileal Neoplasms / surgery. Ileum / innervation. Jejunal Neoplasms / surgery. Jejunum / innervation. Neoplasm Recurrence, Local / surgery. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Autonomic Nervous System / pathology. Combined Modality Therapy. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Autonomic Nervous System Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11699287.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Zurabiani TA, Charkviani LI, Gersamia GK: [Treatment of malignant ovarian tumours in Georgia in 1990-2000]. Georgian Med News; 2006 Aug;(137):28-31
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of malignant ovarian tumours in Georgia in 1990-2000].
  • The adequate treatment of ovary tumor and the issue of improvement of subsequent results still remain the urgent question of oncology.
  • Our aim is to study the effectiveness of treatment of malignant ovary tumor based on the data of 1990-2000 provided by A.
  • Gvamichava National Oncological Centre, to develop optimal methods of treatment and select the right tactics in order to improve subsequent results for patients with malignant ovary tumor.
  • The research revealed that the epithelial neoplasm (malignant ovary tumor) is 5.2 times more spread than nonepithelial (malignant ovary tumor).
  • In our clinic the preference is given to the operational method combined with further chemotherapy (ch/t) for treatment of malignant ovary tumor.
  • The advantage is given to the radical surgery (59.4%), amputation of uterine appendages and omentum resection (79.3%).
  • In the case of less radical surgery (23%)--amputation of uterine appendages (63.8%), while for non-radical surgery (17.5%)--ovariectomy, omentum resection (60%).
  • The number of radical surgery of epithelial neoplasm 3 times exceeds less radical surgery and 12 times--non-radical surgery, while in the case of non epithelial neoplasm the number of radical surgery is two times more than less radical surgery and 3 times more than that non radical.
  • In 1990-2000 in the National Oncological Centre ch/t without platinum and audrioblastin (44.8%) had been most frequently used for treatment of ovary tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / administration & dosage. Female. Fluorouracil / administration & dosage. Georgia (Republic). Humans. Hysterectomy. Methotrexate / administration & dosage. Ovariectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980738.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Susini T, Olivieri S, Molino C, Castiglione F, Tavella K, Viligiardi R: Ovarian cancer initially presenting as intramammary metastases and mimicking a primary breast carcinoma: a case report and literature review. J Womens Health (Larchmt); 2010 Jan;19(1):169-74
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian cancer initially presenting as intramammary metastases and mimicking a primary breast carcinoma: a case report and literature review.
  • BACKGROUND: Ovarian cancer usually spreads intra-abdominally.
  • CASE REPORT: A 44-year-old obese woman underwent core biopsy of a suspicious mammographic finding histologically consistent with lymph node metastases from breast cancer.
  • Serum tumor markers, including CA 125, were normal, and clinical staging was negative.
  • Accurate re-evaluation of the histological specimens suggested the possible ovarian origin of the tumor.
  • An [(18)F]-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography revealed a 33-mm solid mass with intense metabolic FDG uptake in the right groin and a small simple ovarian cyst with normal FDG uptake.
  • The ovarian cyst was removed laparotomically and was malignant on frozen section.
  • Surgical staging revealed a well-differentiated serous ovarian carcinoma microscopically involving the omentum and massively infiltrating the groin node.
  • After chemotherapy, the patient developed metastases in the contralateral axilla that was removed surgically.
  • The patient is alive with no evidence of disease 20 months after surgical removal of the primary tumor.
  • CONCLUSIONS: Surgeons should be aware that ovarian cancer may rarely metastasize to intramammary and axillary nodes, mimicking a primary breast carcinoma.
  • [MeSH-minor] Adult. Breast. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088673.001).
  • [ISSN] 1931-843X
  • [Journal-full-title] Journal of women's health (2002)
  • [ISO-abbreviation] J Womens Health (Larchmt)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


15. Varras M, Tsikini A, Polyzos D, Samara Ch, Akrivis Ch: Internal hemorrhage caused by a twisted malignant ovarian dysgerminoma: ultrasonographic findings of a rare case and review of the literature. Clin Exp Obstet Gynecol; 2004;31(1):73-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Internal hemorrhage caused by a twisted malignant ovarian dysgerminoma: ultrasonographic findings of a rare case and review of the literature.
  • PURPOSE: Ovarian cancer presents as an acute abdomen very rarely.
  • The purpose of the study is the description of a right ovarian malignant dysgerminoma presenting as an abdominal emergency.
  • The patient was sexually active and bimanual gynecological examination revealed the presence of a large lobulated solid tumor in the position of the right adnexa.
  • Fluid was found in the cul-de-sac and in Morisson's space.
  • The patient underwent right salpingo-oophorectomy and biopsy of the omentum.
  • Pathologic analysis revealed a malignant dysgerminoma of the right ovary, expanding to the mesosalpinx.
  • The patient was assigned to FIGO Stage IIC and referred for platinum-based chemotherapy.
  • CONCLUSION: Ovarian malignant dysgerminoma may present as an acute abdomen because of torsion, passive blood congestion, rupture of superficial tumoral vessels and subsequent intra-abdominal hemorrhage.
  • Ovarian dysgerminoma should be part of the differential diagnosis in a young woman with acute surgical abdomen and a solid heterogeneous pelvic mass detected by ultrasonographic scan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14998196.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Mayerhofer-Gallenbacher N, Hudelist G, Czerwenka K: Immunohistochemical analysis of a primary ovarian leiomyosarcoma. Case report. Anticancer Res; 2003 Jul-Aug;23(4):3433-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary ovarian leiomyosarcoma is an extremely rare malignant smooth muscle neoplasm.
  • CASE REPORT: Surgical exploration in a 71-year-old woman revealed a large left adnexal tumor and one separate metastatic implant in one part of the omentum, being classified as a primary ovarian leiomyosarcoma stage III C.
  • The patient was treated with an adjuvant chemotherapy regimen consisting of cisplatin and ifosfamide.
  • High cellularity, nuclear polymorphism as well as patchy necrosis and large areas of hemorrhage, characterized the tumor.
  • Immunohistochemically, the tumor showed a strong positive staining reaction for muscle actin, alpha-smooth muscle actin and neuron-specific enolase as well as a weak positive reaction for vimentin.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12926085.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / Lymphokines; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


17. Bodner K, Bodner-Adler B, Czerwenka K, Hudelist G, Kimberger O, Leodolter S, Mayerhofer K: Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case report. Wien Klin Wochenschr; 2003 Mar 31;115(5-6):191-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary ovarian leiomyosarcoma is an extremely rare malignant smooth-muscle neoplasm with fewer than 30 documented cases worldwide.
  • Surgical exploration revealed a large left adnexal mass that had developed from the left ovary and infiltrated one part of the omentum adherent to the left adnexa.
  • Microscopically the left adnexal tumor consisted of spindle cells arranged in smooth-muscle bundles and fascicles.
  • The tumor was characterized by high cellularity and nuclear polymorphism, as well as patchy necrosis and large areas of hemorrhage.
  • The tumor appeared encapsulated, and the capsule was partially disrupted by tumor cells.
  • Immunohistochemically, the tumor showed a strong staining reaction for muscle actin, alpha-SMA and neuron-specific enolase, and also a weak reaction for vimentin.
  • According to the FIGO staging system for ovarian cancer, the tumor was classified as a primary ovarian leiomyosarcoma stage III C, and the patient was treated with an adjuvant chemotherapy regimen consisting of cisplatin and ifosfamide.
  • Two days after the third cycle of cisplatin/ifosfamid she developed an apoplexy spontaneously and chemotherapy was therefore discontinued.
  • In order to understand more about the nature and the behaviour of this highly malignant neoplasm and to be able to improve the treatment, the prognostic value of bcl-2 has to be investigated in additional studies.
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Ovariectomy. Ovary / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Postgrad Med. 1993 Jul-Sep;39(3):151-3 [8051647.001]
  • [Cites] Gynecol Oncol. 1987 Sep;28(1):116-20 [3308653.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1003-7 [7734290.001]
  • [Cites] Exp Cell Res. 1991 Aug;195(2):277-83 [2070813.001]
  • [Cites] Gynecol Oncol. 1993 Mar;48(3):389-93 [8462904.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1941-52 [8952529.001]
  • [Cites] N Engl J Med. 1993 Sep 2;329(10):690-4 [8393963.001]
  • [Cites] Arch Pathol Lab Med. 1991 Sep;115(9):941-5 [1929791.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1658-64 [10408415.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1097-8 [1648446.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(3):172-3 [10410877.001]
  • [Cites] Pathol Int. 2000 Feb;50(2):162-5 [10792777.001]
  • [Cites] J Obstet Gynaecol Res. 2000 Dec;26(6):401-7 [11152324.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):499-504 [8133533.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):293-9 [8989276.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(14):5214-8 [3523487.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):745-8 [12445253.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(3):257-61 [9641226.001]
  • [Cites] Gynecol Oncol. 1997 Sep;66(3):519-25 [9299270.001]
  • [Cites] Gynecol Oncol. 1987 Feb;26(2):183-92 [3643159.001]
  • [Cites] Am J Obstet Gynecol. 1972 Jan 15;112(2):183-91 [4109398.001]
  • (PMID = 12741081.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


18. Dillman RO, Beutel LD, De Leon C, Nayak SK: Short-term tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer. Cancer Biother Radiopharm; 2001 Jun;16(3):205-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer.
  • OBJECTIVE: We tried to establish short-term cultures of autologous tumors from patients with breast carcinoma for potential use as active specific immunotherapy (i.e., autologous vaccine) after resection of primary breast cancer, and/or for the treatment of metastases.
  • METHODS: Between 10/90 and 12/99 the cell biology laboratory of the Hoag Cancer Center attempted to establish short-term tumor cell lines from 115 breast cancer specimens from 56 primary breast lesions, 17 axillary nodes, 14 other lymph node/soft tissue sites, 10 chest wall recurrences, and 6 thoracentesis of malignant pleural effusions.
  • Success was defined by growth of 5 x 10(7) viable cells whose malignant nature and breast cancer origin was confirmed by histology of the submitted tissue, cell morphology and antigenic phenotyping.
  • RESULTS: Expansion to 5 x 10(7) cells was achieved for only 8/115 samples [7%] including two from chest wall recurrences, and one each from a supraclavicular node, an umbilical node, liver, omentum, and pleural fluid.
  • Two of the successful cell lines were established from tissue that originally had been cryopreserved; the others were initiated from fresh tumor.
  • Tumor cell lines were successfully established from metastatic lesions ranging in size from < 1.0 g to 19 g.
  • Four patients were treated with their autologous vaccine in the setting of chemotherapy-refractory metastatic disease without any significant toxicity.
  • CONCLUSIONS: We were unable to establish short-term cell lines for most patients with primary or metastatic breast cancer using this methodology.
  • Treatment with the autologous irradiated cell product was not associated with acute toxicity.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy. Cancer Vaccines / therapeutic use. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Lymph Nodes / pathology
  • [MeSH-minor] Autoantigens / immunology. Female. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Tumor Cells, Cultured / immunology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11471485.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Cancer Vaccines
  •  go-up   go-down


19. Cass DL, Hawkins E, Brandt ML, Chintagumpala M, Bloss RS, Milewicz AL, Minifee PK, Wesson DE, Nuchtern JG: Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period. J Pediatr Surg; 2001 May;36(5):693-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/PURPOSE: Ovarian pathology, although rare in children, must be included in the differential diagnosis of all girls who present with abdominal pain, an abdominal mass, or precocious puberty.
  • Of those presenting with acute abdominal pain (n = 59), 25 (42%) had ovarian torsion (14 associated with a mature teratoma), and only 1 (2%) had a malignant tumor.
  • There was no age difference between those with benign disease (9.9 +/- 5.6 years; n = 96) and those with malignant tumors (8.6 +/- 3.9 years, n = 10).
  • Nine children had 10 operations for presumed malignant tumors (3 dysgerminomas, 2 immature teratomas with foci of yolk sac tumor, 2 juvenile granulosa cell tumors, 1 yolk sac tumor, and 1 Sertoli-Leydig cell tumor).
  • These patients all had unilateral salpingo-oophorectomy, 4 had chemotherapy, and all are now disease free at 8.4 +/- 4.1 years follow-up.
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Adult. Age Distribution. Age Factors. Age of Onset. Biopsy. Child. Child, Preschool. Diagnosis, Differential. Disease-Free Survival. Fallopian Tubes / surgery. Female. Follow-Up Studies. Hospitals, Pediatric. Humans. Infant. Infant, Newborn. Omentum / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11329568.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Misić M, Vidas Z, Skegro D, Kocman B, Jelić-Puskarić B, Kardum-Skelin I: Fine needle aspiration cytology of adrenocortical carcinoma--case report. Coll Antropol; 2010 Jun;34(2):665-9
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ultrasonography (US) revealed a solitary tumor mass, eight cm in size, of the right adrenal gland.
  • Laboratory tests showed it to be a hormonally active, androgen secreting tumor (elevated testosterone level), which was consistent with the clinical picture of the disease.
  • After histopathological analysis tumor was signed out as adrenocortical carcinoma, a low risk carcinoma according to Weiss' classification.
  • The finding was verified by computerized tomography and the patient was reoperated on.
  • Exploration revealed secondary growth in the region of greater omentum, without infiltration of adjacent organs.
  • 8 months after the second operation and after 6 chemotherapy cycles according to EAP protocol, control CT showed enlarged para-aortic lymph nodes and a node along the upper pole of the right kidney.
  • Cytologic opinion was recidive of primary malignant disease.
  • ACC is a rare malignant epithelial tumor of adrenal cortical cells, with high malignant potential.
  • Morphologically (histopathology and cytology), differential diagnosis includes adenoma on the one hand, and renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) on the other hand.
  • A combined evaluation of clinical features, size or weight, microscopic appearance, immunohistochemical and molecular genetic data is necessary to ensure a correct diagnosis.
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Fatal Outcome. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698150.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


21. Ueda T, Emoto M, Fukuoka M, Miyahara D, Horiuchi S, Tsujioka H, Kawarabayashi T: Primary leiomyosarcoma of the fallopian tube. Int J Clin Oncol; 2010 Apr;15(2):206-9
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary sarcoma of the fallopian tube is a very rare neoplasm.
  • The preoperative diagnosis was a left adnexal malignant tumor based on pelvic examination, abdominal computed tomography, and magnetic resonance imaging.
  • The patient subsequently received adjuvant chemotherapy with pirarubicin and ifosfamide.
  • Thirty months after the first therapy, a computed tomography scan revealed metastasis of the liver, lung, and supraclavicular lymph node.
  • The patient died of the disease 39 months after the initial treatment.
  • [MeSH-major] Fallopian Tube Neoplasms / diagnosis. Leiomyosarcoma / diagnosis
  • [MeSH-minor] Aged. Biopsy. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Hysterectomy. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymph Node Excision. Lymphatic Metastasis. Magnetic Resonance Imaging. Omentum / surgery. Ovariectomy. Rectum / pathology. Rectum / surgery. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Apr;61(1):27-30 [8626112.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):460-9 [12798712.001]
  • [Cites] J Obstet Gynaecol Br Commonw. 1973 Aug;80(8):759-60 [4725957.001]
  • [Cites] Acta Obstet Gynecol Scand. 1992 Apr;71(3):224-5 [1317647.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):626-32 [6344983.001]
  • [Cites] Br J Radiol. 2008 Jan;81(961):73-81 [17681989.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):329-34 [18534250.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):363-6 [16439005.001]
  • [Cites] Eur J Gynaecol Oncol. 2005;26(3):333-5 [15991540.001]
  • [Cites] Gynecol Oncol. 1993 Dec;51(3):404-7 [8112653.001]
  • [Cites] Am J Obstet Gynecol. 1958 Jan;75(1):180-2 [13487699.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1498-506 [15042685.001]
  • [Cites] Zentralbl Gynakol. 1997;119(5):237-40 [9281259.001]
  • (PMID = 20191300.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Iwamoto I, Yanazume S, Fujino T, Yoshioka T, Douchi T: Leydig cell tumor in an elderly patient with complete androgen insensitivity syndrome. Gynecol Oncol; 2005 Mar;96(3):870-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leydig cell tumor in an elderly patient with complete androgen insensitivity syndrome.
  • Testicular tumors often develop in patients with AIS, Sertoli cell tumor and seminoma being the most common types.
  • Leydig cell tumor in AIS is extremely rare.
  • CASE: A large abdominal tumor developed in a 73-year-old female patient.
  • The patient underwent the extirpation of bilateral gonads including the tumor, pelvic lymph nodes, omentum and appendix vermiformis.
  • The pathological diagnosis was malignant Leydig cell tumor of the left testis.
  • There was no adjuvant radiation or chemotherapy performed.
  • CONCLUSION: We reported an extremely rare case of malignant Leydig cell tumor developing in an elderly AIS patient.
  • [MeSH-major] Androgen-Insensitivity Syndrome / complications. Leydig Cell Tumor / complications. Ovarian Neoplasms / complications


23. Morisaki T, Matsunaga H, Beppu K, Ihara E, Hirano K, Kanaide H, Mori M, Katano M: A combination of cyclosporin-A (CsA) and interferon-gamma (INF-gamma) induces apoptosis in human gastric carcinoma cells. Anticancer Res; 2000 Sep- Oct;20(5B):3363-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modulation of interferon-gamma effect by other drug may enhance its tumor specific activity.
  • We found that a combination of cyclosporin-A (CsA) and recombinant interferon-gamma (rIFN-gamma) induced significant apoptosis in all four types of human gastric carcinoma cells tested but not in normal cells such as human peripheral blood mononuclear cells (PBMCs), human omentum-derived mesothelial cells, or human umbilical vein endothelial cells (HUVECs) in vitro.
  • A streptococcal preparation, OK-432, was administered intraperitoneally for the management of 12 gastric cancer patients with malignant ascites.
  • These results indicated that both recombinant and endogenous IFN-gamma can induce potent tumor-apoptosis when combined with CsA.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. Stomach Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Ascitic Fluid / metabolism. Cyclosporine / administration & dosage. Drug Interactions. Enzyme-Linked Immunosorbent Assay. Humans. Immunosuppressive Agents / administration & dosage. Injections, Intraperitoneal. Interferon-gamma / administration & dosage. Interferon-gamma / metabolism. Picibanil / therapeutic use. Recombinant Proteins. Tacrolimus / administration & dosage. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11131636.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Recombinant Proteins; 39325-01-4 / Picibanil; 82115-62-6 / Interferon-gamma; 83HN0GTJ6D / Cyclosporine; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


24. Yan TD, Haveric N, Carmignani CP, Bromley CM, Sugarbaker PH: Computed tomographic characterization of malignant peritoneal mesothelioma. Tumori; 2005 Sep-Oct;91(5):394-400
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computed tomographic characterization of malignant peritoneal mesothelioma.
  • New approaches to treatment using cytoreductive surgery and intraperitoneal chemotherapy suggest that long-term survival is possible in selected patients.
  • Early recognition of this disease process with an orderly surgical approach will begin to optimize treatment.
  • METHODS: Thirty-three patients with malignant peritoneal mesothelioma had CT scans available for review.
  • A Z-score was used to evaluate the incidence of cancer at a particular anatomic site as compared to a general incidence of disease at all sites.
  • In an analysis of 16 abdominopelvic anatomic sites, the vesical or rectal uterine pouch was involved in 97% and the greater omentum in 91%.
  • CONCLUSIONS: Malignant peritoneal mesothelioma by CT evaluation predominates in tumor mass within the central and pelvic portions of the abdomen.
  • With the use of the Z-score and interpretative small bowel findings a radiologic characterization of this disease for primary radiologic diagnosis is possible.
  • [MeSH-major] Mesothelioma / diagnostic imaging. Peritoneal Neoplasms / diagnostic imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459635.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Eisenberg BL, Judson I: Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol; 2004 May;11(5):465-75
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
  • Gastrointestinal stromal tumor (GIST) is a neoplasm of the gastrointestinal tract, mesentery, or omentum that expresses the protein-tyrosine kinase KIT (CD117) and is the most common mesenchymal tumor arising at these sites.
  • Surgical resection is the first-line intervention for operable GISTs, particularly localized primary tumors, and it was historically the only effective treatment.
  • Imatinib is a potent, specific inhibitor of KIT that has demonstrated significant activity and tolerability in the treatment of malignant unresectable or metastatic GIST, inducing tumor shrinkage of 50% or more or stabilizing disease in most patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / surgery. Neoplasm Metastasis. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Imatinib Mesylate. Neoadjuvant Therapy. Patient Selection. Prognosis. Risk Assessment. Stromal Cells. Survival Analysis

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15123459.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 88
  •  go-up   go-down






Advertisement